Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of ARV-471 in Japanese patients with ER+/HER2- advanced breast cancer
jRCT2041220057Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2022
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoint: Dose-limiting toxicities (DLTs). Started Aug 2022; status: active, not recruiting.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2041220057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220057.